Switching Regimen in Treating Cirrhotic HCV GT1b Subjects

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
This is a prospective, randomized study to evaluate the efficacy and safety of switching treatment from Peg-interferon and Ribavirin to direct-acting antiviral agents in Chinese with CHC genotype 1b infection, who are interferon/ribavirin-intolerant.
Epistemonikos ID: b0836b84ee0a5d10c26a3ed942f18969c6f6d7f0
First added on: May 12, 2024